Analysis Report on Grand Health International (02211.HK) Being Included in Hong Kong Stock Market Surge List
Unlock More Features
Login to access AI-powered analysis, deep research reports and more advanced features

About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.
Related Stocks
Grand Health International (02211.HK) is a healthcare company listed in Hong Kong [0]. On December 12, 2025, the stock was listed as a popular stock on the Hong Kong Stock Market Surge List of the East Money App [0]. As of the analysis, no clear short-term breaking news or catalysts were found [0]. Historical financial data shows that the company achieved revenue of RMB 712 million in the 2025 fiscal year, a year-on-year decrease of 34.7%; it recorded a loss of RMB 26.01 million, turning from profit to loss compared to the previous year [2]. Although the interim loss narrowed to RMB 8.01 million in February 2025, it was still in a loss position [4]. On May 13, 2025, the company issued new shares at a price of HKD 0.08 per share, a 1.23% discount to the closing price of the previous trading day [3].
- The surge of this stock may be more related to the overall sentiment of the Hong Kong stock market, dynamics of the healthcare sector, or short-term speculative trading, rather than based on improvements in the company’s fundamentals [0].
- Recent media attention has mainly focused on large healthcare enterprises (such as Alibaba Health, JD Health), and no significant reports targeting 02211.HK have been found [1][2][3].
- The company’s performance turned from profit to loss with a significant decline in revenue, which forms a sharp contrast with the current stock price surge, raising questions about the sustainability of the increase [2].
- Poor financial performance: The performance in the 2025 fiscal year declined sharply, turning from profit to loss, and the subsequent profitability is questionable [2].
- Liquidity risk: Stock trading may be relatively thin, leading to large price fluctuations [0].
- Speculative risk: Without clear catalysts, short-term gains may not be sustainable, and there is a risk of correction [0].
No clear short-term opportunities have been found so far. It is recommended to pay attention to any new announcements from the company or industry news to evaluate the sustainability of the price trend [0].
Grand Health International (02211.HK) was included in the Hong Kong Stock Market Surge List on December 12, 2025, but its increase lacks clear news catalysts. The company’s performance in the 2025 fiscal year was poor, with revenue decreasing by 34.7% and turning from profit to loss. Despite the short-term speculative rise, investors should view the sustainability of the increase cautiously and pay attention to potential correction risks [0][2].
Insights are generated using AI models and historical data for informational purposes only. They do not constitute investment advice or recommendations. Past performance is not indicative of future results.
About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.